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OBJECTIVE—Members of the family of bone morphogenetic
proteins (BMPs) are important regulators of adipogenesis. We
examined the role of the BMP receptor 1A gene (BMPR1A) in the
pathophysiology of human obesity.
RESEARCH DESIGN AND METHODS—We measured
BMPR1A mRNA expression in paired samples of visceral and
subcutaneous adipose tissue from 297 subjects and sequenced
the BMPR1A in 48 nonrelated white subjects. Twenty-one repre-
sentative variants including HapMap tagging single nucleotide
polymorphisms (SNPs) were then genotyped for association
studies in German whites (n  1,907). For replication analyses,
we used a population of Sorbs from Germany (n  900) and
German childhood cohorts (n  1,029 schoolchildren and 270
obese children).
RESULTS—mRNA expression of the BMPR1A was signiﬁcantly
increased in both visceral and subcutaneous adipose tissue of
overweight and obese subjects compared with lean subjects (P 
0.05). In a case-control study, four SNPs (rs7095025, rs11202222,
rs10788528, and rs7922846) were nominally associated with
obesity (adjusted P  0.05). For three SNPs (rs7095025,
rs11202222, and rs10788528), the association with obesity was
conﬁrmed in the independent cohort of Sorbs (adjusted P 
0.005). Consistent with this, BMPR1A SNPs were nominally
associated with obesity-related quantitative traits in nondiabetic
subjects in both adult cohorts. Furthermore, homozygous carri-
ers of the obesity risk alleles had higher BMPR1A mRNA
expression in fat than noncarriers.
CONCLUSIONS—Our data suggest that genetic variation in the
BMPR1A may play a role in the pathophysiology of human
obesity, possibly mediated through effects on mRNA expression.
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R
ecent advances in the ﬁeld of genetics of com-
plex diseases succeeded in identiﬁcation of
novel genes associated with human obesity (1–
6). However, in contrast to fat mass and obesity
associated (FTO) that turned out to be the ﬁrst robustly
replicated susceptibility signal for polygenic obesity (1,2),
several other genes such as GAD2 and INSIG2 failed to
“survive” replication efforts following initial studies (7,8).
Therefore, along with the highly powered genome-wide
association studies highlighting both expected and unex-
pected genes/variants, the candidate gene approach focus-
ing on genes with plausible functional relevance can still
substantially contribute to a better understanding of the
etiology of complex disorders such as obesity and its
sequelae.
Bone morphogenetic proteins (BMPs) are members of
the transforming growth factor- (TGF-) superfamily and
are involved in control of multiple key steps of embryonic
development and differentiation (9–11). BMPs have been
shown to have different roles in adipogenesis depending
on the differentiation stage, the concentrations of BMP, as
well as the presence of other extracellular and intracellu-
lar factors (12–15). Cellular responses to BMPs have been
shown to be mediated by the formation of a hetero-
oligomeric complex of the type 1 and type 2 BMP recep-
tors (16–18). Among different isoforms, three type 1
receptors (BMPR1A/ALK3, BMPR1B/ALK6, and ACVR1A/
ALK2) and three type 2 receptors (BMPR2, ACTR2A, and
ACTR2B) mediate most of the effects of BMPs (9). Of the
different BMPR isoforms, BMPR1A is particularly interest-
ing to adipocyte biology since it has been shown to
specialize in adipocyte differentiation in vitro (19). There-
fore, BMPR1A seems to be a convincing candidate gene
possibly involved in the pathogenesis of human obesity
and type 2 diabetes.
Here, we examined the role of BMPR1A in the patho-
physiology of human obesity. We measured mRNA expres-
sion of BMPR1A in paired samples of visceral and
subcutaneous adipose tissue and examined its relation
with anthropometric traits such as BMI, waist-to-hip ratio
(WHR), and measures of glucose metabolism. Further, we
investigated whether genetic variation within the BMPR1A
might affect adipose tissue BMPR1A mRNA expression.
Twenty-one representative variants including HapMap tag-
ging single nucleotide polymorphisms (SNPs) were ini-
tially genotyped for association studies in German whites.
For replication analyses, we used a population of Sorbs
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dren and obese children).
RESEARCH DESIGN AND METHODS
Adult cohorts: Leipzig cohort. A total of 941 patients with type 2 diabetes
and 966 nondiabetic subjects were recruited at the University Hospital in
Leipzig, Germany. The nondiabetic subjects included 330 men and 666 women
(mean age 49  14 years; mean BMI 29.2  6.6 kg/m
2; mean WHR 0.94  0.17;
mean fasting plasma glucose 5.31  0.59 mmol/l; mean fasting plasma insulin
120  218 pmol/l) and patients with type 2 diabetes included 485 men and 456
women (mean age 64  11 years; mean BMI 29.9  5.8 kg/m
2) (data are given
as arithmetic means  SD). In addition, oral glucose tolerance tests (OGTTs)
and fasting plasma insulin measurements were performed in all nondiabetic
subjects as previously described elsewhere (20). In a subgroup of 423
nondiabetic subjects, insulin sensitivity was assessed with hyperinsulinemic-
euglycemic clamps and plasma leptin measurements were carried out.
Tissue studies. Paired samples of visceral and subcutaneous adipose tissue
were obtained from a subgroup of 297 white men (n  143) and women (n 
154), who underwent open abdominal surgery (described in detail elsewhere)
(20); age range 16–99 years and BMI 18–62 kg/m
2. In addition to above-
mentioned clinical parameters, in these subjects abdominal visceral and
subcutaneous fat area was calculated using computed tomography scans at
the level of L4-L5 and percentage body fat was measured by dual-energy X-ray
absorptiometry.
Assays and measures of obesity and glucose metabolism. Fasting plasma
insulin was measured with an enzyme immunometric assay for the IMMULITE
automated analyzer (Diagnostic Products, Los Angeles, CA). Plasma leptin
levels were assessed by radioimmunoassay (Linco Research, St. Charles, MO).
The OGTT was performed after an overnight fast with 75 g standardized
glucose solution (Glucodex Solution 75 g; Merieux, Montreal, Canada) and
insulin sensitivity was assessed with the hyperinsulinemic-euglycemic clamp
method as described elsewhere (21,22).
Sorbs. The cohort was derived from the self-contained Sorbian population in
Germany. Extensive phenotyping included standardized questionnaires for
past medical history and family history, collection of anthropometric data
(weight, height, WHR), and OGTT. Insulin was measured with the Auto-
DELFIA Insulin assay (PerkinElmer Life and Analytical Sciences, Turku,
Finland). Nine hundred Sorbian subjects (726 subjects with normal glucose
tolerance [NGT], 72 subjects with impaired glucose tolerance [IGT], and 102
cases with type 2 diabetes) were available for the present study (mean age
48  16 years; mean BMI 27.2  5.0 kg/m
2; mean WHR 0.87  0.10; mean
fasting plasma glucose 5.53  1.16 mmol/l; mean fasting plasma insulin 45 
102 pmol/l). For the estimation of the association with glucose and insulin
levels, only nondiabetic subjects were included (deﬁnition according to the
American Diabetes Association criteria) (23). Because the complete family
structure of all subjects is not known, the estimated effect sizes might be
biased by cryptic relatedness in this sample. All studies were approved by the
ethics committee of the University of Leipzig, and all subjects gave written
informed consent before taking part in the study.
Childhood cohorts: Leipzig schoolchildren cohort. This cohort is part of
the Leipzig Schoolchildren Project that investigated anthropometric and
clinical parameters in 2,675 children aged 6–17 years from 1999 to 2000 (24).
DNA was available from 1,029 children (488 boys and 541 girls; mean age 12 
3 years; mean BMI-SDS 0.11  0.97). The BMI was standardized referring to
national reference data (25), and children with a BMI 1.88 SDS ( 97th
centile) were considered obese. A total of 715 children and adolescents with
BMI between 1.0 SDS and 1.0 SDS (337 boys and 378 girls; mean age 12 
3 years; mean BMI-SDS 0.02  0.54) were selected from the 1,029 school-
children to serve as the healthy normal-weight control group to the Leipzig
obese children cohort.
Leipzig obese children cohort. The 270 white children and adolescents (131
boys and 139 girls, aged 12  4 years; BMI-SDS 2.68  0.57) were recruited
from the obesity clinic at the University Hospital for Children & Adolescents,
Leipzig, Germany. All obese children had a detailed metabolic work-up
including an OGTT as described in detail elsewhere (26). The studies were
approved by the ethical committee of the University of Leipzig.
Analysis of human BMPR1A mRNA expression. Human BMPR1A expres-
sion was measured by quantitative real-time RT–PCR by using SYBR Green
methodology, and ﬂuorescence was detected on an ABI PRISM 7500 sequence
detector (Applied Biosystems, Darmstadt, Germany) as described in detail
elsewhere (20). The following primers were used: human BMPR1A (NCBI
accession no. NM_004329.2) 5 tagttcgctgaaccaataaagg 3 (sense) and 5
gtcagaaaatggagtaacctta 3 (antisense). SYBR Green I ﬂuorescence emissions
were monitored after each cycle. Human BMPR1A mRNA expression was
calculated relative to the mRNA expression of 18S rRNA, determined by a
premixed assay on demand for human 18S rRNA (PE Biosystems, Darmstadt,
Germany). To avoid unspeciﬁc primer-dimer ampliﬁcation, the secondary
structure option was checked and ampliﬁcation of speciﬁc transcripts was
conﬁrmed by melting curve proﬁles at the end of each PCR (cooling the
sample to 68°C and heating slowly to 95°C with measurement of ﬂuores-
cence). The speciﬁcity of the PCR was further veriﬁed by subjecting the
ampliﬁcation products to agarose gel electrophoresis.
Sequencing of the BMPR1A. Sequencing of the BMPR1A was performed
using the Big Dye Terminator (Applied Biosystems, Foster City, CA) on an
automated DNA capillary sequencer (ABI PRISM 3100 Avant; Applied Biosys-
tems). Sequence information and PCR conditions for all oligonucleotide
primers used for variant screening are available upon request.
Genotyping of BMPR1A SNPs. Genotyping of the 21 representative SNPs
(Fig. 3) was done using the TaqMan SNP Genotyping assay according to the
manufacturer’s protocol (Applied Biosystems). To assess genotyping repro-
ducibility, a random 5% selection of the sample was regenotyped in all SNPs;
all genotypes matched initial designated genotypes.
Statistical analyses. Before statistical analysis, nonnormally distributed
parameters were logarithmically transformed to approximate a normal distri-
bution. Differences in genotype frequencies between the obese or diabetic
case and healthy control subjects were compared using logistic regression
analyses. Multivariate linear relationships were assessed by generalized linear
regression models. All analyses were done under the additive model and the
presented P values are adjusted for age and sex (and BMI for glucose traits).
Differences in mRNA expression between visceral and subcutaneous adipose
tissue were assessed using the paired Student’s t test.
P values 0.05 were considered to provide evidence for association and
are presented without correction for multiple hypothesis testing. Only two-
sided P values are provided. The analysis of associations with quantitative
traits was restricted to nondiabetic subjects to avoid diabetes status or
treatment masking potential effects of the variants on these phenotypic traits.
To obtain the combined effect of our two cohorts, we performed a
meta-analysis by using the metan command in STATA based on the estimated
effect sizes of each study and their standard error for quantitative traits. The
meta-analysis was performed in a ﬁxed-effects model by using the Mantel-
Haenszel method.
Statistical analyses were performed using SPSS version 15.0.1 (SPSS;
Chicago, IL) and STATA (version 9.0) (StataCorp LP, College Station, TX).
RESULTS
Visceral and subcutaneous BMPR1A mRNA expres-
sion and obesity. Analysis of 297 paired samples of
visceral and subcutaneous adipose tissue showed signiﬁ-
cantly higher BMPR1A transcript levels in visceral com-
pared with subcutaneous fat (Fig. 1A), independent of sex
(Fig. 1B). There were no differences in either visceral or
subcutaneous BMPR1A expression between men and
women (Fig. 1B). To investigate the expression according
to body fat mass or fat distribution, we performed addi-
tional analyses in subgroups of lean (BMI 25 kg/m
2),
overweight (25 kg/m
2  BMI 30 kg/m
2), and obese (BMI
30 kg/m
2) subjects. Based on computed tomography
scans measurement (L4-L5) of abdominal visceral and
subcutaneous fat areas, obese subjects were further cate-
gorized as predominantly visceral or subcutaneous obese
as deﬁned by a ratio of visceral/subcutaneously fat area
0.5 (20). BMPR1A mRNA expression was signiﬁcantly
increased in both visceral and subcutaneous adipose tis-
sue of 51 overweight and 166 obese (101 subcutaneously
obese and 65 visceral obese) compared with 80 lean
subjects (P  0.001) (Fig. 1C). Further, we asked whether
impaired glucose metabolism in patients with either IGT
(n  24) or type 2 diabetes (type 2 diabetes; n  65) is
associated with altered BMPR1A expression in different
fat depots. Subgroup analyses demonstrated that IGT and
type 2 diabetic subjects were indistinguishable with regard
to BMPR1A mRNA measurements; therefore, these groups
were studied together. Patients with IGT/type 2 diabetes
had signiﬁcantly higher BMPR1A expression in both vis-
ceral and subcutaneous fat compared with NGT (n  208)
subjects (Fig. 1D). In addition, we detected a signiﬁcant
correlation between visceral and subcutaneous BMPR1A
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well as in each of the obesity subgroups (data not shown).
Correlation of BMPR1A mRNA expression with pa-
rameters of obesity, glucose metabolism, and insulin
sensitivity. In 297 subjects, univariate regression analysis
revealed signiﬁcant positive correlations between visceral
BMPR1A mRNA expression and BMI, percent of body fat,
waist, WHR, fasting and 2-h plasma glucose, and fasting
plasma insulin (Table 1; Fig. 2). Subcutaneous BMPR1A
mRNA expression also correlated with BMI, percent of
body fat, waist, WHR, and fasting plasma insulin. There
was an inverse correlation between visceral and subcuta-
neous BMPR1A mRNA expression and glucose uptake
during the steady state of a hyperinsulinemic-euglycemic
clamp (Table 1). The correlations remained unchanged
also after excluding subjects with IGT and type 2 diabetes
(data not shown). The correlation between BMPR1A
mRNA expression in fat and glucose infusion rate during
the steady state of an hyperinsulinemic-euglycemic clamp
remained signiﬁcant even upon adjusting for age, sex, and
percent of body fat (Table 2).
Genetic variation in the BMPR1A. We sequenced the
BMPR1A (13 exons, exon-intron boundaries, 5 and 3
UTRs; 3631 bp, NM_004329.2 in the NCBI GenBank) and
1,200 bp in the 5 region in 48 nonrelated white subjects
(12 lean subjects with NGT, 12 visceral obese, 12 subcu-
taneously obese, 12 with type 2 diabetes). Eight genetic
variants were found (Fig. 3).
In addition, 20 HapMap tagging polymorphisms (27)
(www.hapmap.org) covering 100% of the variation in
BMPR1A locus were genotyped in these 48 DNA samples.
HapMap tagging SNPs were selected from the HapMap
Phase II using the Tagger software according to the
following selection criteria: minor allele frequency 0.05
and r
2 0.8 (28).
Based on linkage disequilibrium, seven of eight SNPs
identiﬁed by sequencing were tagged by at least one of the
HapMap tagging SNPs (linkage disequilibrium with r
2
0.8) (supplemental Table 1, available in an online appen-
dix at http://diabetes.diabetesjournals.org/cgi/content/full/
db08-1458/DC1). Linkage disequilibrium was calculated
among the more common variants (minor allele frequency
0.05) using the EMLD statistical program (https://
epi.mdanderson.org/qhuang/Software/pub.htm) (supplemen-
tal Table 1). One novel SNP (c.2147 	 886 C  T) was unique
and therefore genotyped together with the 20 HapMap tag-
ging SNPs for association studies in German whites (n 
1,907) with detailed metabolic testing. For replication analy-
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FIG. 1. BMPR1A mRNA expression in visceral (Vis) and subcutaneous (SC) adipose tissue in lean obese and type 2 diabetic (T2DM) subjects. The
data are means  SE; the mRNA data were ln transformed to achieve normal distribution; BMPR1A mRNA levels in (A) entire study population
(n  297); (B) men (n  143) and women (n  154); (C) subgroups of lean (BMI <25 kg/m
2; n  80), overweight (25 kg/m
2 < BMI <30 kg/m
2;
n  51), subcutaneous obese (n  101) and visceral obese (n  65) (BMI >30 kg/m
2); (D) subjects with NGT (n  208) and with IGT (n  24);
or with type 2 diabetes (n  65). ***Indicates statistical signiﬁcance at P < 0.001; (C) *** indicates statistical signiﬁcance at P < 0.001 when
compared with visceral expression in lean subjects; and statistically signiﬁcant at ##P < 0.01 and ###P < 0.001, respectively, when compared with
subcutaneous expression in lean subjects.
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DIABETES, VOL. 58, SEPTEMBER 2009 2121ses, we used the Sorbian cohort from Germany (n900) and
children cohorts from Leipzig, Germany (n  1,029 school-
children and 270 obese children). All SNPs were in Hardy-
Weinberg equilibrium (P  0.05).
BMPR1A variants and association with obesity:
Leipzig cohort. In a case-control study including 488 lean
(BMI 25 kg/m
2) and 752 obese (BMI 30 kg/m
2) subjects,
4 of 21 genotyped SNPs (rs7095025, rs11202222,
rs10788528, and rs7922846) were nominally associated
with obesity (P  0.05, adjusted for age and sex). Carriers
of the major alleles were at higher risk of being obese
(ORs ranging from 1.22 to 1.40; Table 3).
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FIG. 2. A: Correlations between visceral (Vis) and subcutaneous (SC) BMPR1A mRNA expression, (B) Vis BMPR1A mRNA expression and
percent of body fat, (C) Vis BMPR1A mRNA expression and BMI, (D) subcutaneous BMPR1A mRNA expression and BMI. Data are ln transformed
to achieve normal distribution.
TABLE 1
Linear regression analyses of visceral and subcutaneous
BMPR1A mRNA expression with anthropometric and metabolic
parameters (n  297)
Vis BMPR1A
mRNA R (P)
SC BMPR1A
mRNA R (P)
Age (years) 0.108 (0.063) 0.105 (0.070)
BMI (kg/m
2) 0.319 (0.001) 0.138 (0.018)
Percent of body fat 0.376 (0.001) 0.208 (0.001)
Waist circumference
(cm) 0.555 (0.001) 0.373 (0.001)
WHR 0.428 (0.001) 0.214 (0.001)
Fasting plasma
glucose (mmol/l) 0.233 (0.001) 0.094 (0.104)
Fasting plasma
insulin (pmol/l) 0.523 (0.001) 0.347 (0.001)
Plasma glucose
(2-h) (mmol/l) 0.304 (0.001) 0.110 (0.137)
GIR 0.504 (0.001) 0.406 (0.001)
GIR, glucose infusion rate during the steady state of the hyperinsu-
linemic-euglycemic clamp; SC, subcutaneous; Vis, visceral.
TABLE 2
Multivariate linear regression analyses of visceral and subcuta-
neous BMPR1A mRNA expression with anthropometric and
metabolic parameters (n  297)
Vis BMPR1A mRNA SC BMPR1A mRNA
-coefﬁcient (P) -coefﬁcient (P)
Model 1
Age (years) 0.02 (0.053) 0.021 (0.088)
Sex 0.156 (0.631) 0.537 (0.178)
Model 2
Age (years) 0.029 (0.003) 0.027 (0.032)
Sex 0.016 (0.960) 0.616 (0.119)
BMI (kg/m
2) 3.732 (0.001) 2.190 (0.004)
Model 3
Age (years) 0.023 (0.017) 0.021 (0.083)
Sex 0.194 (0.532) 0.725 (0.067)
Percent of body
fat 3.284 (0.001) 2.374 (0.001)
Model 4
Age (years) 0.010 (0.286) 0.017 (0.176)
Sex 0.162 (0.599) 0.828 (0.039)
Percent of body
fat 2.969 (0.001) 2.185 (0.002)
GIR 1.692 (0.001) 1.861 (0.001)
GIR, glucose infusion rate; SC, subcutaneous; Vis, visceral.
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were additionally genotyped in the Sorbian cohort for
replication. For three SNPs (rs7095025, rs11202222, and
rs10788528), the association with obesity could be repli-
cated in the Sorbian case-control study (303 lean and 210
obese subjects; adjusted P  0.005) (Table 3).
In a combined analysis including both the Sorbian and
the Leipzig cohort, rs10788528 and rs11202222 showed the
strongest association with obesity (P  4.4 
 10
4 and P 
3.5 
 10
5) (Table 3). The combined effects of the SNPs on
obesity were conﬁrmed in a meta-analysis using the metan
command in STATA based on the estimated effect sizes of
each study and their CIs (data not shown). The results
remained unchanged also after excluding subjects with
type 2 diabetes (data not shown).
BMPR1A variants and association with extended
phenotypes: Leipzig cohort. Consistent with case-con-
trol studies, we found nominal associations between
BMPR1A SNPs and BMI as well as obesity–related quan-
titative traits in 966 subjects without type 2 diabetes. Three
(rs7095025, rs11202222, and rs10788528) of the four SNPs
associated with obesity in case-control studies showed
nominal associations with BMI. As expected, the obesity
risk alleles (major alleles) were associated with higher
BMI and increased plasma leptin concentrations (Table 4
and supplemental Table 2). In addition, rs4933413,
rs11202221, and rs2354354 also showed effects on BMI
and plasma leptin levels (supplemental Table 2). Further-
more, several SNPs (rs17231982, rs7895217, rs2354354,
rs4934274, rs7922846) were nominally associated with 2-h
plasma glucose (Table 4 and supplemental Table 2).
We also assessed the association of the 21 SNPs with
type 2 diabetes in a case-control study including 941 case
subjects with type 2 diabetes and 783 healthy control
subjects with NGT from the Leipzig cohort. No signiﬁcant
association with type 2 diabetes was found under logistic
regression analysis (P  0.05; adjusted for age, sex, and
BMI; data not shown).
Sorbs. The four SNPs nominally associated with obesity
in case-control studies in the Leipzig cohort were also
tested for associations with BMI- and obesity-related traits
in 798 nondiabetic Sorbian subjects. Similar to the Leipzig
cohort, major alleles of the three SNPs (rs7095025,
rs11202222, and rs10788528) were nominally associated
with increased BMI (P  0.01, adjusted for age and sex;
Table 5 and supplemental Table 3). Moreover, these SNPs
were associated with higher mean fasting plasma insulin
(P  0.05, adjusted for age and sex). However, this associa-
tion did not withstand adjustment for BMI (Table 5).
Combined effect of the BMPR1A SNPs in our two study
cohorts were assessed by a meta-analysis. All four SNPs
nominally associated with obesity in the Leipzig cohort
(rs7095025, rs11202222, rs10788528, and rs7922846)
showed associations with BMI. Similar to the combined
analysis of case-control studies on obesity in both cohorts,
the highest P values were obtained for rs11202222 and
rs10788528 (adjusted P  3.4 
 10
5 and 3.0 
 10
5,
respectively; Table 5). Furthermore, in meta-analyses, the
major allele at rs7922846 was nominally associated with
2-h plasma glucose (Table 5), which was because of effects
seen in the Leipzig cohort but not replicated in the Sorbs.
Association analyses in children cohorts. In a case-
control study including 715 lean and 270 obese children,
no signiﬁcant association of the four obesity risk variants
detected in the adults cohorts was found (P  0.05 after
adjusting for age, sex, pubertal stage, and height). In line
with this, the BMPR1A SNPs did not associate with
measures of obesity (BMI, WHR) in either schoolchildren
(n  1,029) or obesity cohort (n  270) (adjusted P  0.05;
data not shown).
BMPR1A variants and association with mRNA ex-
pression. In a subgroup of 232 nondiabetic (NGT 	 IGT)
subjects, homozygous carriers of the obesity risk alleles
for rs7095025, rs11202222, rs10788528, and rs7922846 had
higher BMPR1A fat mRNA expression when compared with
carriers of the nonrisk alleles (supplemental Table 4). The
obesity risk allele A in rs7922846 was nominally associated
with increased visceral mRNA expression (P  0.01 adjusted
for age, sex, and BMI; supplemental Table 4).
DISCUSSION
BMPR1A is one of the three speciﬁc BMP receptors that
are essential for the bone morphogenetic protein signaling
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FIG. 3. Genetic structure and SNPs analyzed in BMPR1A. Eight genetic variants (presented horizontally) were found by direct sequencing of the
BMPR1A and 20 tagging polymorphisms (vertically shown) were selected from the HapMap database (www.hapmap.org). Twenty-one (HapMap
tagging SNPs and the c.2147  886C >T) of the 28 SNPs were representative of their linkage disequilibrium groups and were genotyped in German
whites for association with obesity and related phenotypes. Four of 21 representative SNPs (in vertical boxes) showed signiﬁcant association
with obesity and subphenotypes and were additionally genotyped in the Sorbian and children cohorts for replication. Positions of variants are
relative to the ﬁrst translation initiation site and are based on the mRNA sequence NM_004329.2 (NCBI GenBank). ENSSNP10283989 denotes
a variant from the Ensembl database (www.ensemble.org).
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there is evidence for a role of developmental genes in the
origin of obesity and body fat distribution (30). Therefore,
genes coding proteins such as BMPs or BMPRs seem to be
plausible candidate gene involved in the pathogenesis of
human obesity.
We describe both mRNA expression and genetic analy-
sis of the BMPR1A and its role in the etiology of polygenic
obesity. Consistent with the postulated role of BMPRs in
the pathophysiology of human obesity, we found signiﬁ-
cant differences in mRNA expression in adipose tissue
between lean and obese subjects. Visceral and subcutane-
ous mRNA expression was signiﬁcantly higher in over-
weight and obese individuals compared with lean subjects.
BMPR1A mRNA expression correlated strongly with mea-
sures of obesity such as BMI, percent of body fat, and
WHR, as well as with traits of glucose and insulin metab-
olism. Moreover, the visceral mRNA expression positively
correlated with the subcutaneous expression. Based on
correlations of mRNA expression in adipose tissue with
obesity and relevant metabolic traits, the BMPR1A might
play a relevant role in human obesity. It was shown
recently that in mesenchymal stem cells, BMP-2/4 use
predominantly BMPR1A, whereas BMP-6/7 prefer activin
A receptor, type I (ACVR1A) (31). According to the pro-
posed model, BMP-2/4 induce white fat differentiation, and
BMP-7 specify brown adipogenesis (15). The positive
correlation in the increased expression of BMPR1A with
BMI (and percent of body fat) suggests that overweight or
obese people may have enhanced BMP-2/4 signaling, caus-
ing the increased adiposity.
Further support for the role of BMPR1A in obesity
comes from the genetics part of our study, in which 21
representative variants including HapMap (27) tagging
SNPs were genotyped for association studies in German
whites with detailed metabolic testing. Three of four
variants (rs7095025, rs11202222, rs10788528, and rs7922846)
that were initially nominally associated with obesity in
German whites (the Leipzig cohort) showed association
with obesity also in a second, independent Sorbian cohort.
Besides replicating the initial ﬁndings, these SNPs along
with other variants in BMPR1A were nominally associated
with BMI as well as traits related to glucose and insulin
metabolism. Associations with glucose- and insulin-related
traits appeared to be mediated through obesity as they did
not withstand adjustments for BMI. Because we did not
ﬁnd a relationship between SNPs and measures of fat
distribution including WHR, it is possible that BMPR1A
genotype contributes to whole-body fat mass and not
primarily to fat distribution in human obesity. However,
more sophisticated measures of whole-body fat distribu-
tion are needed to address whether BMPR1A genotype
plays a role in the determination of fat distribution.
Because of the strong correlation of the visceral and
subcutaneous BMPR1A mRNA expression with obesity,
we also asked whether the obesity risk variants have any
inﬂuence on the mRNA expression. In a subgroup of
nondiabetic subjects, homozygous carriers of the obesity
risk alleles for rs7095025, rs11202222, rs10788528, and
rs7922846 had higher BMPR1A fat mRNA expression when
compared with carriers of the nonrisk allele variants. The
obesity risk allele A in rs7922846 was nominally associated
with increased visceral mRNA expression. These ﬁndings
indicate that the SNP effects on obesity and related
metabolic parameters might be mediated through their
effects on mRNA expression. In our study, two BMPR1A
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BMPR1A AND POLYGENIC OBESITY
2124 DIABETES, VOL. 58, SEPTEMBER 2009SNPs (rs3905377 and rs7070369) located 5 upstream of
the translation start site in a putative promoter region
were in strong linkage disequilibrium (r
2  0.80, D1.0)
with the obesity-associated rs7095025. Considering higher
BMPR1A mRNA levels in carriers of the obesity risk alleles
at these SNPs, we used the Transcription Element Search
System (TESS; http://www.cbil.upenn.edu/tess) to exam-
ine transcriptional regulatory sequences surrounding
these genetic variants, which might modify BMPR1A ex-
pression. The region surrounding rs3905377 (T  C)
matches human transcriptional binding sites for a tran-
scription factor IID (TFIID) for the major allele T. TFIID
(alias TATA-binding protein) is required for transcription
by polymerase I, II, and III (32). The region around
rs7070369 (G  A) matches transcriptional binding sites
for the factor E2-early promoter (EIIaE-A) for the major
allele G (33). Even though these data may indicate func-
tional relevance of the noncoding BMPR1A variants in the
putative promoter region, their biological relevance re-
mains to be explored. Alternatively, the BMPR1A haplo-
types might harbor a variant, which controls BMPR1A
mRNA levels but was not tested in our present study as
only exons and potentially regulatory regions were se-
quenced. It is also noteworthy that the only amino acid
changing variant identiﬁed in our study (Pro2Thr;
rs11528010) is in strong linkage disequilibrium with
rs7922846, which showed moderate association with obe-
sity and 2-h plasma glucose. Because the Pro2Thr is
located in the potential BMPR1A signal peptide chain
(1–23 amino acids) it could affect the posttranslational
transport of the BMPR1A. This remains to be clariﬁed in in
vitro studies aimed at intercellular trafﬁcking of the
BMPR1A. We are also aware that coverage of the common
genetic variation in the BMPR1A locus was solely based
on HapMap data along with our own sequencing of the
coding region and that additional variants may have been
identiﬁed by sequencing of introns. We believe that rese-
quencing of the complete BMPR1A locus (with introns) in
appropriate samples (including obese subjects) would
provide a conclusive coverage of genetic variation in the
BMPR1A and might consequently lead to the causal SNPs.
Children represent a particularly interesting study pop-
ulation for identifying primary genetic determinants in-
volved in susceptibility to complex polygenic diseases
such as obesity, because unlike in adults phenotypes they
are less inﬂuenced by comorbidities and prolonged expo-
sure to environmental factors. Lack of association of
BMPR1A variants with childhood obesity indicates that
the SNP effects most likely manifest in later stages of life
and that these effects might be modiﬁed by gene-environ-
ment interactions. Based on our data, BMPR1A does not
seem to be a candidate gene for early-onset obesity.
BMP4 and its high-afﬁnity receptor BMPR1A are ex-
pressed in differentiating and adult -cells, although it is
not required during pancreatic development (34). Trans-
genic expression of BMP4 in mice -cells enhances glu-
cose-stimulated insulin secretion and glucose clearance
(34). In our present study, no association with type 2
diabetes was found suggesting that BMPR1A does not
appear to be a major player in the polygenic etiology of
type 2 diabetes. This is in line with recent genome-wide
association studies that did not identify any variants
within the BMPR1A locus being signiﬁcantly associated
with type 2 diabetes (1).
In conclusion, the role of genetic variation in the
BMPR1A in the pathophysiology of human obesity might
be mediated through effects on mRNA expression. Even
though the correlation analyses do not allow establishing a
true cause relationship chain between obesity and
BMPR1A mRNA expression in adipose tissue, our expres-
sion data together with genetics data suggest that
BMPR1A as well as common genetic variants within the
gene and its untranslated regulatory regions might be
involved in the polygenic etiology of human obesity.
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TABLE 4
Association of BMPR1A obesity risk variants with quantitative traits in the Leipzig cohort
Minor allele
frequency BMI (kg/m
2) WHR
Plasma leptin
(ng/ml)
Fasting plasma
glucose (mmol/l)
Plasma glucose
120 min (mmol/l)
Fasting plasma
insulin (pmol/l)
rs7095025 0.26
P 0.006 0.840 0.0003/0.002 0.441/0.554 0.566/0.457 0.859/0.436
 0.023 0.002 0.358/0.272 0.005/0.004 0.009/0.012 0.016/0.065
SE 0.008 0.009 0.098/0.087 0.007/0.007 0.016/0.016 0.091/0.084
rs11202222 0.22
P 0.004 0.730 0.009/0.036 0.177/0.244 0.804/0.686 0.825/0.449
 0.025 0.003 0.266/0.190 0.009/0.008 0.004/0.007 0.021/0.066
SE 0.009 0.010 0.102/0.09 0.007/0.007 0.016/0.016 0.094/0.087
rs10788528 0.16
P 0.005 0.198 0.101/0.221 0.334/0.423 0.872/0.765 0.470/0.849
 0.028 0.014 0.203/0.134 0.008/0.006 0.003/0.006 0.077/0.019
SE 0.010 0.011 0.124/0.109 0.008/0.008 0.019/0.019 0.107/0.099
rs7922846 0.27
P 0.13 0.07 0.125/0.239 0.290/0.327 0.009/0.01 0.035/0.133
 0.012 0.016 0.156/0.105 0.007/0.006 0.040/0.039 0.190/0.125
SE 0.008 0.009 0.101/0.089 0.006/0.006 0.015/0.015 0.090/0.083
Data represent subjects without type 2 diabetes (n  966). Parameters were ln transformed before analyses. P values were adjusted for age
and sex for all variables; for the variables serum leptin, fasting plasma glucose, fasting plasma insulin, and 2-h plasma glucose, the ﬁrst P value
was calculated after adjusting for age and sex and the second P value after adjusting for age, sex, and BMI.  indicates effect directions of
the major allele in additive mode of inheritance.
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